Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Finished Goods (2016 - 2019)

Tandem Diabetes Care filings provide 6 years of Finished Goods readings, the most recent being $9.7 million for Q1 2019.

  • On a quarterly basis, Finished Goods fell 21.48% to $9.7 million in Q1 2019 year-over-year; TTM through Mar 2019 was $9.7 million, a 21.48% decrease, with the full-year FY2018 number at $10.6 million, down 17.81% from a year prior.
  • Finished Goods hit $9.7 million in Q1 2019 for Tandem Diabetes Care, down from $10.6 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $14.4 million in Q3 2017 to a low of $2.9 million in Q2 2015.
  • Median Finished Goods over the past 5 years was $9.1 million (2016), compared with a mean of $8.5 million.
  • Biggest five-year swings in Finished Goods: skyrocketed 145.5% in 2016 and later decreased 21.48% in 2019.
  • Tandem Diabetes Care's Finished Goods stood at $3.5 million in 2015, then skyrocketed by 109.57% to $7.4 million in 2016, then surged by 73.1% to $12.9 million in 2017, then dropped by 17.81% to $10.6 million in 2018, then decreased by 8.36% to $9.7 million in 2019.
  • The last three reported values for Finished Goods were $9.7 million (Q1 2019), $10.6 million (Q4 2018), and $11.3 million (Q3 2018) per Business Quant data.